Ventilator acquired pneumonia
Conditions
Brief summary
mechanical ventilation-free days (VFD) from extubation through D28. A beneficial effect of using recombinant human interferon gamma-1b would be a statistically significant increase in VFD in patients receiving study drug in this setting compared to the group receiving placebo.
Detailed description
All-cause mortality in intensive care at D28, Bacteriological samples become negative, The occurrence of another episode of VAP before extubation, length of stay in intensive care unit, length of stay at hospital, The evolution of monocytic HLA-DR kinetics, the evolution of leukocytes kinetics, Assessment of the economic efficiency of IFN-γ administration
Interventions
Sponsors
Hospices Civils De Lyon
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mechanical ventilation-free days (VFD) from extubation through D28. A beneficial effect of using recombinant human interferon gamma-1b would be a statistically significant increase in VFD in patients receiving study drug in this setting compared to the group receiving placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality in intensive care at D28, Bacteriological samples become negative, The occurrence of another episode of VAP before extubation, length of stay in intensive care unit, length of stay at hospital, The evolution of monocytic HLA-DR kinetics, the evolution of leukocytes kinetics, Assessment of the economic efficiency of IFN-γ administration | — |
Countries
France
Outcome results
None listed